Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

The BluePearl Pet Hospital in Tampa, Florida, is now offering the transcatheter edge-to-edge repair (TEER) procedure for its ...

BluePearl Pet Hospital in Tampa announced it will now offer a groundbreaking heart procedure for pets, making it only the ...

Inc. (Stock Code: 2500.HK, hereinafter referred to as 'Venus Medtech' or the 'Company'), a global leader in structural heart therapies, has announced financial results for the year ended December 31, ...

The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the patient's heart.

AI algorithms can accurately identify tricuspid regurgitation in echocardiograms, supporting timely diagnosis and ...

A young man’s undiagnosed acromegaly leads to severe cardiac complications, highlighting the genetic links and diagnostic ...

Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...